Weiqing Han

712 total citations · 1 hit paper
23 papers, 382 citations indexed

About

Weiqing Han is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Weiqing Han has authored 23 papers receiving a total of 382 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 10 papers in Surgery and 7 papers in Oncology. Recurrent topics in Weiqing Han's work include Renal cell carcinoma treatment (7 papers), Bladder and Urothelial Cancer Treatments (6 papers) and Prostate Cancer Treatment and Research (6 papers). Weiqing Han is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Bladder and Urothelial Cancer Treatments (6 papers) and Prostate Cancer Treatment and Research (6 papers). Weiqing Han collaborates with scholars based in China, United States and Denmark. Weiqing Han's co-authors include Hong Luo, Chang-Lu Hu, Jiyan Liu, Benkang Shi, Jun Guo, Xinan Sheng, Jianmin Fang, Yanxia Shi, Zhisong He and Jianming Ying and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and BMC Medicine.

In The Last Decade

Weiqing Han

22 papers receiving 376 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

2020 192 citations Xinan Sheng, Xieqiao Yan et al. Clinical Cancer Research profile →

Peers

Weiqing Han

SURGE

ONCOL

PRM

RNMI

Yoshimasa Oku Japan

Bisong Haupt United States

Cian Muldoon Ireland

Matthias Schauer Germany

Xiaoyi Duan China

Daniela Paccagnella Italy

Michihiro Ono Japan

Fan‐ying Liu China

J. Morreau Netherlands

Shengfu Huang China

Yoshimasa Oku Japan

Weiqing Han

175 ×1.0

SURGE

297 ×1.8

ONCOL

125 ×0.9

PRM

72 ×1.0

56 ×0.8

RNMI

Citations per year, relative to Weiqing Han Weiqing Han (= 1×) peers Yoshimasa Oku

Countries citing papers authored by Weiqing Han

Since Specialization

Citations

This map shows the geographic impact of Weiqing Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiqing Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiqing Han more than expected).

Fields of papers citing papers by Weiqing Han

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weiqing Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiqing Han. The network helps show where Weiqing Han may publish in the future.

Co-authorship network of co-authors of Weiqing Han

This figure shows the co-authorship network connecting the top 25 collaborators of Weiqing Han. A scholar is included among the top collaborators of Weiqing Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weiqing Han. Weiqing Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huang, Liang, et al.. (2022). A single‐centre, open‐label, single‐arm, fixed‐sequence pharmacokinetic study of SHR3680 on repaglinide and bupropion in prostate cancer patients. British Journal of Clinical Pharmacology. 89(2). 874–886. 3 indexed citations

Qin, Xiaojian, Dongmei Ji, Weijie Gu, et al.. (2022). Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial. BMC Medicine. 20(1). 84–84. 10 indexed citations

Huang, Liang, Yu Xie, Shusuan Jiang, et al.. (2022). Comprehensive Characterization of Ageing-Relevant Subtypes Associated With Different Tumorigenesis and Tumor Microenvironment in Prostate Cancer. Frontiers in Molecular Biosciences. 9. 803474–803474. 1 indexed citations

Huang, Liang, et al.. (2022). Oxidative Phosphorylation-Related Signature Participates in Cancer Development, and PTPRG Overexpression Suppresses the Cancer Progression in Clear Cell Renal Cell Carcinoma. Journal of Immunology Research. 2022. 1–18. 3 indexed citations

Pu, Yeong‐Shiau, Hanjong Ahn, Weiqing Han, et al.. (2022). Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study. Advances in Therapy. 39(6). 2641–2656. 13 indexed citations

Huang, Liang, Tao Dai, Longzheng Xia, et al.. (2021). SQLE Mediates Metabolic Reprogramming to Promote LN Metastasis in Castration-Resistant Prostate Cancer. OncoTargets and Therapy. Volume 14. 4285–4295. 14 indexed citations

Cao, Jian, et al.. (2021). Correlation Between the Evolution of Somatic Alterations During Lymphatic Metastasis and Clinical Outcome in Penile Squamous Cell Carcinoma. Frontiers in Oncology. 11. 641869–641869. 2 indexed citations

Qu, Yuanyuan, Qing Zou, Hongqian Guo, et al.. (2021). Camrelizumab plus famitinib for advanced renal cell carcinoma or unresectable urothelial carcinoma: Updated results from a phase II trial.. Journal of Clinical Oncology. 39(15_suppl). 4550–4550. 2 indexed citations

Sheng, Xinan, Zhisong He, Weiqing Han, et al.. (2021). An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009).. Journal of Clinical Oncology. 39(15_suppl). 4584–4584. 25 indexed citations

10.

Cao, Jian, Shuai Zhu, Kan Liu, et al.. (2020). Comparison of Renal Artery vs Renal Artery-Vein Clamping During Partial Nephrectomy: A System Review and Meta-Analysis. Journal of Endourology. 34(4). 523–530. 14 indexed citations

11.

Zhu, Shuai, Yong Zeng, Ying Long, et al.. (2020). ADNP Upregulation Promotes Bladder Cancer Cell Proliferation via the AKT Pathway. Frontiers in Oncology. 10. 491129–491129. 10 indexed citations

12.

Zhao, Cheng, Yi Pan, Yinhuai Wang, et al.. (2020). A novel cell-free single-molecule unique primer extension resequencing (cf-SUPER) technology for bladder cancer non-invasive detection in urine. Translational Andrology and Urology. 9(3). 1222–1231. 8 indexed citations

13.

Sheng, Xinan, Xieqiao Yan, Lin Wang, et al.. (2020). Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research. 27(1). 43–51. 192 indexed citations breakdown →

14.

Yu, Wenchang, et al.. (2020). The clinical research of 5 steps sequential method for whole treatment of hemorrhagic radiation cystitis in china. International Journal of Medical Sciences. 18(3). 756–762. 2 indexed citations

15.

Qin, Xiaojian, Weiqing Han, Hong Luo, et al.. (2020). SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study.. Journal of Clinical Oncology. 38(6_suppl). 90–90. 1 indexed citations

16.

Sun, Yinghao, Liping Xie, Tao Xu, et al.. (2019). Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China. Asian journal of urology. 7(3). 301–308. 19 indexed citations

17.

Jiang, Shusuan, Sulai Liu, Yu Xie, et al.. (2015). Recurrent waist tumor subsequent to percutaneous nephrolithotomy: A case report. Oncology Letters. 10(1). 297–300.

18.

Liu, Sulai, et al.. (2014). Malignant priapism secondary to isolated penile metastasis from a renal pelvic carcinoma. Canadian Urological Association Journal. 8(7-8). 558–558. 5 indexed citations

19.

Liu, Sulai, Qiuxia Yu, Weiqing Han, et al.. (2014). Primary gastrointestinal stromal tumor of the prostate: A case report and literature review. Oncology Letters. 7(6). 1925–1929. 18 indexed citations

20.

Liu, Sulai, Lin Qi, Qiuxia Yu, et al.. (2014). Survivin and HLA-I expression predicts survival of patients with clear cell renal cell carcinoma. Tumor Biology. 35(8). 8281–8288. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact